Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Kinnate Biopharma Inc (NQ: KNTE )

1.280 -0.060 (-4.48%)
Streaming Delayed Price Updated: 11:14 AM EDT, Oct 4, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 40,836
Open 1.340
Bid (Size) 1.280 (2)
Ask (Size) 1.290 (2)
Prev. Close 1.340
Today's Range 1.250 - 1.370
52wk Range 1.319 - 12.50
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Analysts Move To Sidelines For Cancer Player Kinnate Biopharma After Restructuring
Monday, Kinnate Biopharma Inc (NASDAQ: KNTE) prioritized the exarafenib combination, KIN-8741, and discovery efforts around its  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 19, 2023
Via Benzinga

Performance

YTD
-78.70%
-78.70%
1 Month
-42.60%
-42.60%
3 Month
-59.37%
-59.37%
6 Month
-79.68%
-79.68%
1 Year
-88.81%
-88.81%

More News

Read More
Why Is Cancer Firm Kinnate Biopharma Stock Trading Lower Today?
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
10 Analysts Have This to Say About Kinnate Biopharma
Via Benzinga
The Latest Analyst Ratings for Kinnate Biopharma
Via Benzinga
Expert Ratings for Kinnate Biopharma
Via Benzinga
What 4 Analyst Ratings Have To Say About Kinnate Biopharma
Via Benzinga
Dell Technologies To Rally More Than 15%? Here Are 10 Other Analyst Forecasts For Tuesday
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Kinnate Biopharma Inc. Announces Pipeline Updates, Strategic Reprioritization and Workforce Restructuring
From Kinnate Biopharma
Via GlobeNewswire
Kinnate Biopharma Inc. Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
From Kinnate Biopharma
Via GlobeNewswire
Kinnate Biopharma Inc. to Participate in Upcoming Investor Conferences
From Kinnate Biopharma
Via GlobeNewswire
Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029
Via FinancialNewsMedia
Kinnate Biopharma in Focus: Analyst's Adjusted Price Target and the Potential of KIN-3248
Via Benzinga
Kinnate Biopharma Inc. Reports First Quarter 2023 Financial Results and Recent Corporate Updates
From Kinnate Biopharma
Via GlobeNewswire
7 Stocks With Promising Upside Potential for 100% Returns
Via InvestorPlace
Trilogy Metals And 2 Other Penny Stocks Insiders Are Aggressively Buying
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Kinnate Biopharma Inc. Adds Two New Drug Candidates to Its Growing Targeted Oncology Pipeline and Provides Cash Runway Guidance
From Kinnate Biopharma
Via GlobeNewswire
First Report of Positive Dose Escalation Data Supports Best-in-Class Profile for Investigational Exarafenib as a Single Agent and in Combination with Binimetinib in BRAF-altered Cancers and NRAS Mutant Melanoma
From Kinnate Biopharma
Via GlobeNewswire
Kinnate Biopharma Inc. Provides Full-Year 2022 Financial Results and Recent Corporate Updates
From Kinnate Biopharma
Via GlobeNewswire
Kinnate Biopharma Inc. to Report First Clinical Data for Its Investigational Pan-RAF Inhibitor, Exarafenib (KIN-2787), in an Oral Presentation at the AACR 2023 Annual Meeting
From Kinnate Biopharma
Via GlobeNewswire
Why Bank Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.